JP6885649B2 - 統合失調症の治療のためのイロペリドン - Google Patents

統合失調症の治療のためのイロペリドン Download PDF

Info

Publication number
JP6885649B2
JP6885649B2 JP2017543816A JP2017543816A JP6885649B2 JP 6885649 B2 JP6885649 B2 JP 6885649B2 JP 2017543816 A JP2017543816 A JP 2017543816A JP 2017543816 A JP2017543816 A JP 2017543816A JP 6885649 B2 JP6885649 B2 JP 6885649B2
Authority
JP
Japan
Prior art keywords
daily dose
iroperidone
day
schizophrenia
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017543816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505901A5 (enExample
JP2018505901A (ja
Inventor
ミハエル、 エイチ． ポリマオプロス、
ミハエル、 エイチ． ポリマオプロス、
クルト、 ディー． ヴォルフガング、
クルト、 ディー． ヴォルフガング、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of JP2018505901A publication Critical patent/JP2018505901A/ja
Publication of JP2018505901A5 publication Critical patent/JP2018505901A5/ja
Application granted granted Critical
Publication of JP6885649B2 publication Critical patent/JP6885649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017543816A 2015-02-17 2016-02-17 統合失調症の治療のためのイロペリドン Active JP6885649B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562117173P 2015-02-17 2015-02-17
US62/117,173 2015-02-17
US201562172436P 2015-06-08 2015-06-08
US62/172,436 2015-06-08
PCT/US2016/018316 WO2016134049A1 (en) 2015-02-17 2016-02-17 Iloperidone for the treatment of schizophrenia

Publications (3)

Publication Number Publication Date
JP2018505901A JP2018505901A (ja) 2018-03-01
JP2018505901A5 JP2018505901A5 (enExample) 2019-03-28
JP6885649B2 true JP6885649B2 (ja) 2021-06-16

Family

ID=55532275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543816A Active JP6885649B2 (ja) 2015-02-17 2016-02-17 統合失調症の治療のためのイロペリドン

Country Status (9)

Country Link
US (2) US10441580B2 (enExample)
EP (1) EP3258935B1 (enExample)
JP (1) JP6885649B2 (enExample)
KR (1) KR102870956B1 (enExample)
CN (2) CN116211857A (enExample)
BR (1) BR112017017608A2 (enExample)
CA (1) CA2976383C (enExample)
ES (1) ES2870498T3 (enExample)
WO (1) WO2016134049A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214827B2 (en) 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
IL321015A (en) * 2022-12-19 2025-07-01 Vanda Pharmaceuticals Inc ILOPERIDONE dosing regimen for the treatment of bipolar I disorder and schizophrenia
AU2024278999A1 (en) 2023-06-02 2025-11-13 Vanda Pharmaceuticals Inc. Method of treatment with iloperidone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370634T3 (es) 2001-08-31 2011-12-21 Novartis Ag Isómeros ópticos de un metabolito de iloperidona.
WO2003037337A1 (en) 2001-10-30 2003-05-08 Novartis Ag Depot formulations of iloperidone and a star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA3113166A1 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
WO2009036056A1 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
HUE053904T2 (hu) 2007-12-19 2021-07-28 Janssen Pharmaceutica Nv Hosszan tartó hatású injektálható paliperidon-észterekkel kapcsolatos adagolási rendek
ES2533091T3 (es) * 2009-05-15 2015-04-07 Vanda Pharmaceuticals Inc. Tratamiento antipsicótico basado en genotipo de SNP de DRD2 o ANKK1
US20140350029A1 (en) 2011-12-02 2014-11-27 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
CN108938632A (zh) 2012-03-14 2018-12-07 万达制药公司 用于治疗精神疾病的伊潘立酮代谢物及其应用
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus

Also Published As

Publication number Publication date
US10987346B2 (en) 2021-04-27
EP3258935B1 (en) 2021-04-07
CA2976383C (en) 2023-05-23
EP3258935A1 (en) 2017-12-27
US10441580B2 (en) 2019-10-15
HK1248551A1 (zh) 2018-10-19
CN116211857A (zh) 2023-06-06
KR20170118830A (ko) 2017-10-25
BR112017017608A2 (en) 2018-05-08
JP2018505901A (ja) 2018-03-01
ES2870498T3 (es) 2021-10-27
CA2976383A1 (en) 2016-08-25
KR102870956B1 (ko) 2025-10-16
US20190388412A1 (en) 2019-12-26
WO2016134049A1 (en) 2016-08-25
US20180021324A1 (en) 2018-01-25
CN107249586A (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
JP7183355B2 (ja) 片頭痛の処置における使用のためのラスミジタンとｃｇｒｐアンタゴニストとの併用療法
AU2018342072B2 (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
JP2015512406A5 (enExample)
CA3075719A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
JP6145946B2 (ja) 併用ａｌｓ療法
WO2019067413A1 (en) USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
JP6885649B2 (ja) 統合失調症の治療のためのイロペリドン
JP2015522077A5 (enExample)
EP2767287B1 (en) Agent for preventing or treating htlv-i associated myelopathy
CN102149389A (zh) 生物素化艾屈肝素用于降低抗血栓治疗期间出血发生率的用途
HK1248551B (en) Iloperidone for the treatment of schizophrenia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210507

R150 Certificate of patent or registration of utility model

Ref document number: 6885649

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250